Literature DB >> 3608990

Multiple c-myb transcript cap sites are variously utilized in cells of mouse haemopoietic origin.

R J Watson, P J Dyson, J McMahon.   

Abstract

Mouse c-myb gene transcripts in various cells of haemopoietic origin were analysed using S1 nuclease and RNase mapping techniques and by Northern blotting. It was found that the prevalent 3.8-kb c-myb mRNA present in thymocytes, T cell leukaemias, myelomonocytic leukaemias, erythroleukaemias and myeloid stem cells was initiated at several cap sites mapping within a region 97-244 bp upstream from the protein coding sequence. Utilization of additional cap sites mapping further upstream was also observed in certain cells, most notably thymocytes, and this gave rise to RNA species (4.3-5.6 kb) larger than the presumptive mRNA. In contrast, myeloma cell c-myb transcripts, which are much less abundant than those in more immature haemopoietic cells, were found to be initiated at a restricted set of cap sites mapping 244-277 bp upstream of the coding sequence. Hence, these data suggest that the abundance of the c-myb mRNA may be regulated by a process involving selective utilization of mRNA cap sites. Sites hypersensitive to DNase I were associated with mRNA cap sites in cells that expressed c-myb.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608990      PMCID: PMC553537          DOI: 10.1002/j.1460-2075.1987.tb02413.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  37 in total

1.  Separation and characterization of herpes simplex virus type 1 immediate-early mRNA's.

Authors:  R J Watson; C M Preston; J B Clements
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

2.  Complementation patterns of Thy-1 variants and evidence that antigen loss variants "pre-exist" in the parental population.

Authors:  R Hyman; V Stallings
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

3.  Retention of lymphocyte characteristics by myelomas and theta + -lymphomas: sensitivity to cortisol and phytohemagglutinin.

Authors:  P Ralph
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

4.  Analysis of red blood cell differentiation.

Authors:  P R Harrison; N Affara; P S Goldfarb; K Kasturi; Q S Yang; A Lyons; J O'Prey; J Fleming; E Black; R Nichols
Journal:  Adv Exp Med Biol       Date:  1982       Impact factor: 2.622

5.  A bacteriophage lambda vector for cloning large DNA fragments made with several restriction enzymes.

Authors:  W A Loenen; W J Brammar
Journal:  Gene       Date:  1980-08       Impact factor: 3.688

6.  Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene.

Authors:  K H Klempnauer; T J Gonda; J M Bishop
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

7.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers.

Authors:  J Vieira; J Messing
Journal:  Gene       Date:  1982-10       Impact factor: 3.688

8.  Autoinduction of differentiation in WEHI-3B leukemia cells.

Authors:  D Metcalf; N A Nicola
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

9.  Differential expression of the amv gene in human hematopoietic cells.

Authors:  E H Westin; R C Gallo; S K Arya; A Eva; L M Souza; M A Baluda; S A Aaronson; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

10.  The product of the retroviral transforming gene v-myb is a truncated version of the protein encoded by the cellular oncogene c-myb.

Authors:  K H Klempnauer; G Ramsay; J M Bishop; M G Moscovici; C Moscovici; J P McGrath; A D Levinson
Journal:  Cell       Date:  1983-06       Impact factor: 41.582

View more
  18 in total

1.  Differential transcription of exon 1 of the human c-fms gene in placental trophoblasts and monocytes.

Authors:  J Visvader; I M Verma
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

Review 2.  Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells.

Authors:  Yohei Maeshima
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

3.  Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.

Authors:  Y Maeshima; N Kashihara; T Yasuda; H Sugiyama; T Sekikawa; K Okamoto; K Kanao; Y Watanabe; Y S Kanwar; H Makino
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

4.  Hematopoietic lineage-specific heterogeneity in the 5'-terminal region of the chicken proto-myb transcript.

Authors:  W K Kim; M A Baluda
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

5.  Structure and biological activity of the transcriptional initiation sequences of the murine c-myb oncogene.

Authors:  P W Sobieszczuk; T J Gonda; A R Dunn
Journal:  Nucleic Acids Res       Date:  1989-12-11       Impact factor: 16.971

6.  Structural organization of upstream exons and distribution of transcription start sites in the chicken c-myb gene.

Authors:  S L Hahn; M Hahn; W S Hayward
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

7.  Expression of the c-myb and c-myc genes is regulated independently in differentiating mouse erythroleukemia cells by common processes of premature transcription arrest and increased mRNA turnover.

Authors:  R J Watson
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

8.  Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation.

Authors:  K Todokoro; R J Watson; H Higo; H Amanuma; S Kuramochi; H Yanagisawa; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of Tcells and is required for PKB-mediated protection from apoptosis.

Authors:  A Lauder; A Castellanos; K Weston
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

10.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.

Authors:  R Morishita; G H Gibbons; M Horiuchi; K E Ellison; M Nakama; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.